Medicines Management Optimisation Achieving your 5 a day post-mi Medication WORKSHOP

Similar documents
CARDIAC REHABILITATION PROGRAMME:- MEDICATION

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

NES Asthma Hospital Medication Care Plan 7

Ischaemic Heart Disease

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Volume 2; Number 11 July 2008

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

CONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition

PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI)

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

NICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Nurse Prescribing in Cardiology. Jan Keenan Consultant Nurse; NMP Lead

Practice-Level Executive Summary Report

Indigestion (dyspepsia)

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

Rapid access chest pain clinic (RACPC)

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

QOF Indicator DM013:

APPENDIX 2F Management of Cholesterol

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Inverclyde CHP Protected Learning Event- Heart Failure

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Commissioning for value focus pack

Acute Coronary Syndromes: Challenges to Management. Claire Williams November 2017

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09

Review guidance for patients on long-term amiodarone treatment

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Flolan. Potent pulmonary and systemic vasodilator Three major potential pharmacologic actions

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Preventive Cardiology Scientific evidence

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

Case study Chest Pain treating angina without a bypass or stent

2010 ACLS Guidelines. Primary goals of therapy for patients

Primary Prevention of Stroke

Steps Against Recurrent Stroke (STARS)

Medicine Dr. Omed Lecture 2 Stable and Unstable Angina

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

MPharmProgramme. Hypertension (HTN)

Reducing risk in heart disease

MRCP(UK) PACES. INFORMATION FOR THE CANDIDATE Training Scenario N 001 SAMPLE HOST CENTRE Station 5: BRIEF CLINICAL CONSULTATION

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Belinda Green, Cardiologist, SDHB, 2016

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME. Indicator Assessment Report

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126.

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

5.2 Key priorities for implementation

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11

Identification and management of familial hypercholesterolaemia (FH) - An overview

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention

Frimley Health Area Prescribing Committee

Coronary Artery Disease

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA

Overview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead

Primary Prevention Patients aged 85yrs and over

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove

Teresa Neal. Pippa Travers-Mason. Aboriginal Health Worker. Consultant clinical pharmacist MPH, Med, BPharm AACPA

CKD and risk management : NICE guideline

Medications and your Heart. RBCH Foundation Trust

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care

Cardiovascular Pharmacotherapy

Arrhythmia Care in the DGH What Still Needs to be Done? Dr. Sundeep Puri Consultant Cardiologist

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Adherence to health behaviour advice in heart failure

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Pharmaceutical Care of People with Atrial Fibrillation. Course information

Coronary Heart Disease. Iqbal Malik

E-portfolio guide. This guide will take you through, step by step, the type of information we expect you to record at each stage of your cycle.

Helen Williams Consultant Pharmacist for CV Disease - South London

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

ACE. Inhibitors. Quiz feedback

Transcription:

Medicines Management Optimisation Achieving your 5 a day post-mi Medication WORKSHOP

What is Medicines Optimisation? the safe and effective use of medicines to enable the best possible outcomes NICE ng 5 2015

What do BACPR S&CC say? 3.5.1 Cardioprotective Medication Current use of cardioprotective medication should be assessed (inc adherence) with the aim of ensuring uptitration of medication during the programme so that evidence-based dosages are achieved. Patients beliefs about medication should also be assessed as this affects adherence to drug regimens Key drugs: antiplatelets, lipid-lowering, betablockers, ACE-I/AIIRA, calcium channel blockers, anticoagulants, diuretics

What do CC for HBC&E say? Recognise opportunities and barriers to implementing interventions Agree goals for the intervention Implement behaviour change in a manner consistent with its underlying philosophy Make and review action plans based on identified goals Carry out health behaviour problem solving End the intervention in a planned manner and to plan for long term maintenance of the new health behaviours

What about non-medical prescribing? Aims: Medicine access patient choice increased more efficient and quicker Improve access to advice & services; Good use of appropriately skilled & placed healthcare workforce Includes allowing doctors to make best use of their expertise Contribute to an integrated seamless healthcare system; Increase capacity to meet the increased demand for the provision of new and existing NHS services; Improve patient care without compromising patient safety

Medicines Optimisation achieving 5-a-day as part of cardiac rehabilitation 0. General post-mi 1. Single / dual antiplatelet therapy 2. ACE-I / AIIRA 3. Statin 4. Betablocker 5. GTN 5. PPI

0. General post-mi medication

0. General post-mi medication Reduced morbidity & mortality Reduce progression of disease (CHD. ACS. HF) Keenness to follow instructions High contact with CR for modifications, answers, info Address misconceptions Fit with lifestyle Instil ownership History & Examination Usual effects & s.effects of medications vs those of post-mi Effective system for your team & area Negotiation, communication, listening, pt-centred skills Guidelines Newness forgetting medication, lack of fit Wellness need not felt Side-effects of medication vs s.effects of post-mi Ownership. Whose job is it? Time for assessment, review, up-titration, follow-up Access to notes System safe, effective, individualised, aspirational CR play its part in the bigger picture: pt. relative. GP. PN. Cardiologist. Pharmacist. Daily News. Others Role of self Education & information opportunities

1. Anti-platelet: single / dual

1. Anti-platelet: single / dual Reduce platelet aggregation DAPT for time-limited period Bruising Bleeding Upper GI symptoms BD forgetfulness Misunderstanding of need for both synergistic effect Past gastric ulceration/issue, bleeding hx, age, anaemia. AF Surgery Anticoagulant Abdominal tenderness Aspirin: with or without water; with food Communicate length of therapy Doors and windows - DAPT Guidelines?

2. ACE-I / AIIRB

2. ACE-I / AIIRB Prevent HF. Reduced morbidity & mortality Re-introduction post revascularisation Up-titration. Down-titration Monitoring Sx, U&E, BP Symptomatic low BP Cough Angioedema. Renal failure. Bilateral RAS Ownership over titrations Past intolerance cough, angioedema, bilateral RAS Renal function Diuretics. Potassium supplementation Hypertension. HF U&E 7 days post up-titration Guidelines? Planned what to do if; monitoring; holidays Shared care GP, PN, Cardiologist, CR team nonprescribers, PATIENT Communication

3. Statin

3. Statin Reduce mortality and morbidity Improve the numbers lower LDL & cholesterol (when to test?) Reduce vascular inflammation, stabilise plaque Up-titrate. Down-titrate. Switch Past intolerance really? Alcohol excess Liver function test Familial hyperlipidaemia. Simon Broom criteria Lipid levels Guidelines? Simvastatin circadian rhythm forgetfulness Myopathy vs new exercise effect Keeping up with the latest news My cholesterol is normal Establishing on suitable, effective drug & dose Cost? Monitoring muscular aches CK after 2 day exercise-free symptomic only With exercise (HDL), weight loss, healthy eating Familial hypercholesterolaema nurse

4. Betablocker

4. Betablocker Up to 1 year post MI Reduce symptoms in HF Improve survival Up-titration. Down-titration. De-prescribing Timing Wheeze. Tiredness. Cold peripheries. ED. Mood Bradycardia. Heart block. Asthma 5 day dip post up-titration Reduced hypoglycaemia warning Chest conditions. Intolerance. Pulmonary oedema. Unstable HF Hypertension. Angina Guidelines? Planned what to do if; monitoring; holidays Shared care GP, PN, Cardiologist, CR team nonprescribers, PATIENT Communication

5. Nitrolingual spray

5. Nitrolingual spray Peripheral vasodilatation Increase confidence Reduce fear Reduce unnecessary re-admission Prophylaxis when pattern established Join with what to do if advice Past use. Associations of past use at MI ED & use of PDE5 inhibitors Trial in your clinic? Guidelines? Headaches. Hypotension Dyspepsia vs angina vs MSK vs anxiety Fear of use inevitable admission fear Embarrassment. Family concern Taste associated with effectiveness PDE5 inhibitors Avoid scare-induction Panic! I ve forgotten my spray Review if new or increased need for spray

5. PPI

5. PPI Prophylaxis in view if DAPT plus Reduce unnecessary re-admissions with CP Encourage best time of day empty stomach Appropriate referral for review Up-titration. Down-titration. De-prescribing Weight loss. Healthy eating. Alcohol & nicotine reduction or cessation Past tolerance and intolerance Chest and abdo exam & palpation Anaemia Guidelines? Gastric upset try another Not all fit with Clopidogrel Head and Shoulders effect Systemic effect of Aspirin & DAPT Start as in-pt CR review & alter or refer GP Information

Considerations for achieving 5 a day My role in medication optimisation As non-medical prescriber in CR As non-prescriber in CR Systems in place or not in place How I fit into the bigger team with patient, family, community pharmacist, GP, practice nurse, cardiologist; working together How can I and my team alter my / our / the system so it fits? A good start Improving my/our role with one medication Use resources team, guidelines made easy, web, forums, associations Audit results & share to improve care; NMC revalidation

go forth & optimise Any questions or comments?